Kornimate/medical-research-clean huggingface dataset:
the application of real-time near-infrared imaging in gynecological surgery

Conditions: Cervical Cancer; Ovarian Tumor; Endometrial Carcinoma; Uterine Myomatosis; Adenomyosis; Ovarian Cyst Benign; Ovarian Cyst Malignant; Endometriosis; Uterine Sarcoma

Summary: removing in situ and metastasis lesions completely during gynecological surgery is central to reduce the recurrence and death, and the identification of lesions in traditional gynecological surgery often depends on the experience of surgeons. the identification of nerves is often needed in gynecological surgery, such as the obturator nerves in pelvic lymphadenectomy, and the pelvic autonomic nerves in nerve-sparing radical hysterectomy for cervical cancer. nerve identification also relies heavily on the experience of surgeons. this project aims to realize the identification of lesions and nerves under the navigation of indocyanine green fluorescent imaging, and evaluate the accuracy of fluorescent imaging of lesions and the effectiveness of nerves identification by near-infrared imaging. this project may reduce the recurrence or death caused by residual lesions and postoperative dysfunction caused by nerves injury, thus, improve the survival rate and quality of life for patients with gynecological diseases.


Eligibility criteria:
inclusion criteria: * patients with figo (2018) stage ia1(lvsi)-iia2 cervical cancer，endometrial cancer，ovarian tumor, endometriosis, adenomyosis, uterine myomatosis, ovarian cyst ,or uterine sarcoma * patients who consent to receive indocyanine green near-infrared fluorescence-guided gynecological surgery exclusion criteria: * less than 6 months expectancy life; * patients with iodine allergy.
is there any relation between serum anti-p53 antibody and tlg, mtv and suv as pet parameters in lung cancer patients?

Conditions: Lung Neoplasms; Gene, p53

Summary: p53 is a tumor suppressor gene which plays an important role in controlling normal cell proliferation regulation that is located on the chromosome 17 (17p13.1). it is the most common goal of genetic alteration in many tumors. serum p53 protein is presence in normal healthy individuals. however p53 antibody is extremely rare. mutations in this gene cause an accumulation of non-functional proteins and development of anti-p53 antibodies, which can be detectable in tissues, slouhed cells, blood and other body fluids. some studies have reported that, p53 mutations are highly common in leukemia, lymphoma, lung, esophagus, stomach, liver, bone, bladder, ovarian, and brain cancers. lung cancer is the most common cause of cancer-related deaths and the survey is low after the initial diagnosis. accurate staging is important for determine the choice of treatment and predict prognosis. 18f-fdg pet/bt has important value for initial staging and it is the most advanced imaging technique developed all over the world for determine of the characterization of the metabolic tumor volume. maksimum standardized uptake value (suvmax) which was acquired by pet imaging is commonly used in clinical practice as a criterion for malignancy. due to the development of new software programs recently studies have shown that metabolic tumor volume (mtv) and total lesion glycolysis (tlg) may be useful quantitative parameters for the prognostic evaluation. viable tumor volume could be estimate with this programs.the purpose of this study was to assess the relation between serum anti-p53 antibody level and quantitative pet parameters as suvmax, suvave, mtv and tlg.


Eligibility criteria:
inclusion criteria: * patients who were referred to our department with the purpose of 18f-fdg pet/ct imaging for staging due to lung cancer diagnosis * patients who were performed 18f-fdg pet/ct for diagnosis in the cause of the suspected pulmonary nodule/lesion in thorax ct but not detected pathologic fdg accumulation * in the control group, healthy subjects with no history of cancer and without any complaint exclusion criteria: * patients had operated for lung cancer, received prior chemotherapy or radiotherapy for lung cancer, with no definitive histological diagnosis, and a blood glucose level greater than 150 mg/dl

Keywords: anti-p53 antibody pet/ct lung cancer fdg
patients with asymptomatic hyperuricemia have stronger local inflammatory response and worse outcome after total knee arthroplasty

Conditions: Arthritis Knee

Summary: we identify all patients who had undergone primary total knee arthroplsty(tka) from april 1, 2015, to march 30, 2016. patients are grouped by uric acid level. the knee society score(kss score) and the hospital for special surgery knee score (hss score) before the surgery and 6 years after the surgery will be collected. also the clinical data will be collected.


Eligibility criteria:
inclusion criteria: * patients who had undergone primary tka from april 1, 2015, to march 30, 2016 exclusion criteria: * (1) infection, (2) rheumatoid arthritis, (3) ankylosing spondylitis, (4) revision surgery, (5) patients with unicondylar knee replacement, (6) patients who have been diagnosed with gout or previous gouty symptoms, and (7) patients combined with preoperative redness or swelling.
pediatric pneumonia lung ultrasound

Conditions: Pneumonia; Acute Respiratory Infection

Summary: the purpose of this study is to evaluate the impact of lus on the diagnosis and management of childhood pneumonia in developing countries


Eligibility criteria:
inclusion criteria (chest indrawing cases): * male or female, 2 through 23 months of age * cough \<14 days or difficulty breathing * visible indrawing of the chest wall, with or without fast breathing * ability and willingness of child's caregiver to provide informed consent and to be available for follow-up for the planned duration of the study, including accepting a home visit if he/she fails to return to the study facility for a scheduled follow-up visit inclusion criteria (non-chest indrawing controls): * male or female, 2 through 23 months of age * cough \<14 days or difficulty breathing * ability and willingness of child's caregiver to provide informed consent and to be available for follow-up for the planned duration of the study, including accepting a home visit if he/she fails to return to the study facility for a scheduled follow-up visit

Keywords: pneumonia diagnostic ultrasound pakistan mozambique
intrinsic rv - inhibition of unnecessary rv pacing with av search hysteresis in icds

Conditions: Tachycardia

Summary: intrinsic rv is a two-armed randomized trial that will compare the effects of innovative dual-chamber pacing with av search hysteresis to standard vvi among icd patients.

the purpose of study is to assess whether avsh will provide benefits of a dual-chamber icd without the deleterious effects of unnecessary rv pacing. this study will aim to demonstrate that dddr-avsh is equal to vvi with respect to mortality and hf hospitalizations.

Eligibility criteria:
inclusion criteria: * patients who meet vitality™avt® icd indications * patients who sign and date a patient informed consent prior to device implant * patients who remain in the clinical care of the enrolling physician exclusion criteria: * patients with current indication for crt-d * patients who previously had a pacemaker, icd or crt-d * patients with chronic af * patients whose life expectancy is \<12 months due to other medical conditions * patients who are expected to receive a heart transplant during the duration of the study * patients with epicardial pacing leads * patients who have cabg, pci, cardiac or other arrhythmia surgery planned but not yet performed * patients with or who are likely to receive a tricuspid or other valve prosthesis * patients who are currently enrolled in another investigational study that would directly impact the treatment or outcome of the current study * patients who are younger than 18 years of age * patients who are pregnant * patients who are mentally incompetent and cannot give patient informed consent or participate in the study

Keywords: right ventricular pacing implantable cardioverter defibrillator
knuch cadai-b-1(kcb-1)

Conditions: Breast Neoplasm; Female

Summary: the cadai-b (computer aided design artificial intelligence-breast) system is a real-time ai diagnostic tool for breast ultrasound. it integrates with ultrasound devices to detect suspicious lesions, providing size, bi-rads, and malignancy probability. after installation and user training, the system displays real-time breast conditions and automatically analyzes lesions when a freeze frame is set, showing results in seconds. this study will assess cadai-b\&#39;s accuracy and reliability by comparing its findings with biopsy results.


Eligibility criteria:
inclusion criteria: * women aged 20 years or older * individuals scheduled to undergo breast ultrasound for diagnostic evaluation * patients whose ground truth can be determined through biopsy, surgery, or follow-up exclusion criteria: * images containing artifacts that may affect the interpretation * presence of breast implants * significant breast trauma or mastitis at the time of the breast ultrasound that could cause distortion in image interpretation * history of surgery or chemotherapy

Keywords: breast neoplasm ultrasound
percutaneous hemodynamic support with impella 2.5 during scar-related ventricular tachycardia ablation

Conditions: Ventricular Tachycardia

Summary: the purpose of this research study is to evaluate the safety and feasibility of the impella 2.5 circulatory support system for use during mapping and ablation of ventricular tachycardia in the setting of ventricular dysfunction.

the impella 2.5 is a percutaneous heart pump that will be used to provide partial circulatory support -. the impella 2.5 is approved by the us food and drug administration and is being tested to see if it helps keep the patient's blood pressure stable during the cardiac ablation procedure. the impella 2.5 circulatory support system works by placing a small pump into the left pumping chamber of the heart which will then help the heart circulate blood throughout the body. the impella 2.5 circulatory support system will be removed once the heart no longer needs help with the pumping action which can be at any time from just after the completion of the heart procedure up to several days post procedure as determined by physician.

Eligibility criteria:
inclusion criteria: * male or female * age 18 to 90 years * catheter ablation of ventricular tachycardia * left ventricular ejection fraction less than or equal to 40% or hypertrophic cardiomyopathy exclusion criteria: * any reversible cause of vt \[electrolyte derangements, medication related itc\] * evidence of active, ongoing cardiac ischemia as the cause of vt * patients who have experienced any cerebral ischemic event including any tia in the preceding one month * mural thrombus in left ventricle * presence of mechanical aortic valve * severe aortic stenosis \[orifice area of 2.0 cm2 or less\] or moderate to severe aortic insufficiency * severe abnormalities of the aorta that would preclude impella insertion, including aneurysms and extreme tortuosity or calcifications * liver dysfunction or markedly abnormal coagulation parameters \[as defined by platelet count less than or equal to 50,000/ul\] * any condition resulting in contraindication to anticoagulation \[eg gi bleeding\] * women who are known to be pregnant or have had a positive b-hcg test 7 days prior to procedure * patients whose life expectancy is less than one year * mental impairment precluding patient or family from providing informed consent or completing the appropriate follow up

Keywords: ventricular tachycardia radio frequency ablation percutaneous left ventricular assist device hemodynamic management interventional cardiac procedure mechanical cardiac assistance intra-aortic balloon pump coronary intervention impella 2.5 circulation support system
bending adolescent depression trajectories through personalized prevention

Conditions: Depression

Summary: investigators will combine risk factor research and evidence-based prevention programs, to advance knowledge on personalized approaches to prevention that may be able to better "bend trajectories" of depression that surge throughout adolescence.

investigators will innovatively combine risk factor research and evidence-based prevention programs, to advance knowledge on personalized approaches to prevention that may be able to better "bend trajectories" of depression that surge throughout adolescence. a randomized controlled trial will examine the benefits of matching youth to two depression prevention programs of interpersonal psychotherapy-adolescent skills training (ipt-ast) and coping with stress (cws) for the prevention of depression in adolescents. these two programs are designed to address distinct risk factors for depression - cws addresses cognitive risks and ipt-ast addresses interpersonal risks. a total of 210 participants across two sites, university of denver and rutgers university, will be stratified on cognitive and interpersonal risk and randomized to the two conditions. the goals of the study are to (1) demonstrate that prevention programs can modify depression trajectories among youth by examining within person changes in trajectories over time (three years before and three years after the prevention programs) and by comparing trajectories of prevention youth with changes in same aged cohorts; (2) evaluate a personalized prevention approach to bending depression trajectories by matching and mismatching youth to either cws or ipt-ast based on individual risk profiles; (3) examine mechanisms of bending depression trajectories and test whether the prevention programs operate via their hypothesized processes; and (4) explore how genetic susceptibility, emotion regulation, and temperament may affect individual response to ipt-ast and cws. by implementing evidence-based prevention programs after 3-years of prospective naturalistic data collection, this study will contribute essential data on personalized medicine and altering developmental trajectories of first-onset depression.

Eligibility criteria:
inclusion criteria: * currently in the 6th to 11th grades * adolescent and parent must be english-speaking * parental consent and adolescent consent exclusion criteria: * presence of current major depressive disorder, dysthymia, bipolar disorder, or significant psychosis * suicide attempt in the past week or significant suicidal ideation in the past week * presence of significant psychopathology or significant pervasive developmental delays that would make the group inappropriate

Keywords: depression prevention adolescents
the effects of sacubitril-valsartan vs enalapril on left ventricular remodeling in st-elevation myocardial infarction

Conditions: STEMI

Summary: the primary objective of the peri-stemi trial is to assess whether sacubitril-valsartan is more effective in preventing adverse lv remodeling for patients with st-elevation myocardial infarction (stemi) than enalapril.


Eligibility criteria:
inclusion criteria: * aged between 18 - 75 years old * first-time st-segment elevation myocardial infarction based on the newest esc guidelines * timely primary percutaneous coronary intervention within 12 hours from onset * written informed consent acquired exclusion criteria: * known history of or persistent clinical chronic heart failure prior to randomization * previous use of arni, or intolerance or contraindications to study drugs including arni or acei * history of significant chronic coronary obstruction and adverse ventricular remodeling * history of any cardiomyopathy, valvular heart disease, congenital heart disease, stent or cabg, or planned open-heart surgery within 3 months * history of hepatic impairment or history of cirrhosis with evidence of portal hypertension * history of chronic renal dysfunction, or egfr \< 30 ml/min/1.73 m2 * history of malignancy and with a life span less than one year * patients with a known history of angioedema related to previous aceis/arb therapy. * with contraindication to mri examination (pacemaker and claustrophobia) or cannot finish breath-holding when lying on the examination bed * pregnancy or nursing women

Keywords: st-elevation myocardial infarction (stemi) cardiovascular magnetic resonance (cmr) angiotensin receptor neprilysin inhibitor (arni) angiotensin-converting enzyme inhibitor (acei)
the clinical study aims to assess the quality of donor livers using hyperspectral imaging.

Conditions: Liver Transplantation; Hyperspectral Imaging

Summary: based on hyperspectral imaging equipment, this project collected hyperspectral imaging data of donor livers, analyzed various parameters, investigated the detection capability of hyperspectral imaging for assessing donor liver quality, gathered patient prognosis information, examined the correlation between early postoperative complications and hyperspectral imaging data, and explored characteristic parameters for evaluating donor liver quality using hyperspectral imaging technology. the occurrence of early complications was predicted.

hyperspectral imaging (hsi) is an advanced optical technology that combines spectroscopy and imaging, providing a non-destructive approach for clinical diagnosis. in recent years, hyperspectral imaging has emerged as a prominent research topic in the field of applied medicine. liver transplantation is considered the most effective treatment for end-stage liver disease; however, the scarcity of donor livers and the growing number of patients awaiting transplantation pose significant challenges to global organ transplantation. the evaluation of donor livers has always been a focal point in liver transplantation. currently, clinical evaluation relies heavily on subjective judgment by transplant physicians based on general appearance and touch assessments, along with clinical examinations and pathological biopsy results. nevertheless, studies have demonstrated that these methods are not entirely reliable for assessing liver quality. therefore, it is crucial to identify additional evaluation parameters and establish a convenient, reliable, and non-invasive method to assess donor liver quality. this study aims to analyze hyperspectral imaging data alongside clinical test data and recipient complications occurring between june 2022 to june 2024 to evaluate the quality of donor livers using hyperspectral imaging technology while exploring potential evaluation parameters.

Eligibility criteria:
inclusion criteria: 1. recipients ranged in age from 18 to 65 2. donor age ≥ 18 years exclusion criteria: 1. recipients are younger than 18 years or older than 65 years 2. donor younger than 18 years 3. secondary liver transplantation. 4. multiple organ transplantation.

Keywords: liver transplantation hyperspectral imaging evaluation of donor liver early complications
computer guided versus conventional surgical removal of deeply impacted mandibular third molar with preservation of external oblique ridge

Conditions: Impacted Third Molar Tooth

Summary: in patent have deeply impacted lower third molar ,dose computer guided enhance surgical outcome versus conventional surgical remove of wisdom teeth

p- patient with deeply impacted mandibular molar i- computer guided surgical cutting stent c- conventional extraction o- clinical outcome sound radiographic outcomes primary outcome - pain : each patient well be asked to rate current and worst pain intensity on visual analogue scale (vas ) of 0-10 with zero being no pain and ten corresponds to the worst pain. secondary outcome * evaluation of maximum inter incisal opening: assessment of mmo will be performed by measuring the distance in mm between the incisal edges of the upper and lower central incisor by using tape graduated method. * evaluation of edema throw use nylon thread.

Eligibility criteria:
inclusion criteria: * patient with deeply impacted mandibular third molar * patients should be free from any systematic disease that affect normal healing exclusion criteria: * -patient with soft tissue impaction and impaction class a position 1 * medical problem that may interfere with the procedures such as bleeding disorder \& pregnant. * uncooperative patient.
carboplatin, taxane and ramucirumab for patients with nsclc after pemetrexed or pembrolizumab maintenance

Conditions: Non-small Cell Lung Cancer

Summary: the purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. this study will also assess whether it is safe to combine these drugs.


Eligibility criteria:
inclusion criteria: * advanced non-squamous nsclc (stage iv or recurrent after initial curative intent therapy) in adults age 18 or older * prior exposure to 4-6 cycles of pem/carbo/pembro and pd after at least 18 weeks of maintenance pemetrexed, pembrolizumab or the combination of the two. * ps 0-1 exclusion criteria: * presence of a driver mutation that is susceptible to targeted therapy * other active invasive malignancy requiring ongoing therapy * grade 2 or higher sensory neuropathy * evidence of untreated brain metastases * history of bleeding diatheses or recent, antecedent hemoptysis (\> 1/2 teaspoon in prior 2 months)
safety and efficacy study of rp4010, in patients with relapsed or refractory lymphomas

Conditions: Lymphoma

Summary: a phase i/ib, study to evaluate safety and efficacy of rp4010, in patients with relapsed or refractory lymphomas

safety: treatment-emergent adverse events (ae); treatment related ae, serious adverse events (sae) and clinical significant ae; dose limiting toxicities (dlt). pharmacokinetics (pk): peak plasma concentration (cmax), area under the plasma concentration versus time curve (auc), time of maximum concentration observed (tmax). efficacy: overall response rate (orr), progression free survival (pfs); overall survival (os) and duration of response (dor).

Eligibility criteria:
inclusion criteria: * refractory to or relapsed after at least 1 prior treatment line. * eastern cooperative oncology group (ecog) performance status ≤2 * patients must be ≥18 years of age * able to give a written informed consent. exclusion criteria: * patients receiving cancer therapy within 3 weeks prior to cycle1 day1 (c1d1). * patients with active hepatitis b virus (hbv), hepatitis c virus (hcv) or human immune deficiency virus (hiv) infection * patients who received allo-stem cell transplantation(allo-sct) within 12 months. * patients with graft versus-host disease (gvhd) * subjects who have received drugs that directly or indirectly inhibit calcineurin or nuclear factor of activated t cells (nfat) activity . * patient with symptomatic, or history of documented congestive heart failure (ny heart association functional classification iii-iv); * patient with frederica's (qtcf) formulas (qtcf) ≥450 msec; * patient with angina not well-controlled by medication; * women who are pregnant or lactating.